| 孙丽燕,李景莉,李亚楠,李宏锦,王淑珍.舒血宁注射液联合倍他司汀对椎-基底动脉供血不足性眩晕症患者椎-基底动脉血流速度和氧化应激的影响[J].现代生物医学进展英文版,2022,(14):2748-2752. |
| 舒血宁注射液联合倍他司汀对椎-基底动脉供血不足性眩晕症患者椎-基底动脉血流速度和氧化应激的影响 |
| Effects of Shuxuening Injection Combined with Betahistine on Vertebrobasilar Blood Flow Velocity and Oxidative Stress in Patients with Vertebrobasilar Insufficiency Vertigo |
| Received:January 07, 2022 Revised:January 31, 2022 |
| DOI：10.13241/j.cnki.pmb.2022.14.030 |
| 中文关键词: 舒血宁注射液 倍他司汀 椎-基底动脉供血不足性眩晕症 血流速度 氧化应激 |
| 英文关键词: Shuxuening injection Betahistine Vertebrobasilar insufficiency vertigo Blood flow velocity Oxidative stress |
| 基金项目:张家口市重点研发计划项目（1921115D）；河北省自然科学基金项目（H2015105062） |
|
| Hits: 823 |
| Download times: 407 |
| 中文摘要: |
| 摘要 目的：观察舒血宁注射液联合倍他司汀对椎-基底动脉供血不足性眩晕症（VBIV）患者椎-基底动脉血流速度和氧化应激的影响。方法：纳入河北北方学院附属第一医院神经内科2019年5月~2021年3月期间收治的91例VBIV患者，根据信封抽签法将患者分为对照组和研究组，例数分别为45例和46例。对照组、研究组患者分别接受倍他司汀、舒血宁注射液联合倍他司汀治疗，两组均治疗1个月。观察两组疗效、椎-基底动脉血流速度、氧化应激、血液流变学及药物安全性。结果：对照组（68.89%）的临床总有效率明显低于研究组（91.30%），差异有统计学意义（P<0.05）。研究组治疗1个月后椎动脉（左侧、右侧）和基底动脉的平均血流速度高于对照组（P<0.05）。研究组治疗1个月后谷胱甘肽过氧化物酶（GSH-Px）、过氧化物歧化酶（SOD）高于对照组（P<0.05）。研究组治疗1个月后全血高切黏度（HSV）、红细胞压积（HCT）、丙二醛（MDA）、红细胞沉降率（ESR）、全血低切黏度（LSV）低于对照组（P<0.05）。治疗期间，两组均未发生明显的不良反应情况。结论：VBIV患者采用舒血宁注射液联合倍他司汀治疗，可改善椎-基底动脉血流速度和血液流变学，减轻机体氧化应激，疗效可靠。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effects of Shuxuening injection combined with betahistine on vertebrobasilar blood flow velocity and oxidative stress in patients with vertebrobasilar insufficiency vertigo (VBIV). Methods: 91 patients with VBIV who were treated in Department of Internal Medicine-Neurology, The First Affiliated Hospital of Hebei North University from May 2019 to March 2021 were included. According to the envelope lottery method, the patients were divided into control group and study group, with 45 cases and 46 cases respectively. The patients in the control group and the study group were treated with betahistine, Shuxuening injection combined with betahistine respectively. Both groups were treated for 1 month. The curative effect, blood flow velocity of vertebrobasilar artery, oxidative stress, hemorheology and drug safety in the two groups were observed. Results: The total clinical effective rate of the control group (68.89%) was significantly lower than that of the study group (91.30%), the difference was statistically significant (P<0.05). one month after treatment, the average blood flow velocity of vertebral artery (left and right) and basilar artery of the study group were higher than those of the control group (P<0.05). one month after treatment, the glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) of the study group were higher than those of the control group (P<0.05). One month after treatment, whole blood high shear viscosity (HSV), hematocrit (HCT), malondialdehyde (MDA), erythrocyte sedimentation rate (ESR) and whole blood low shear viscosity (LSV) of the study group were lower than those of the control group (P<0.05). There were no obvious adverse reactions in the two groups during treatment. Conclusion: The treatment of patients with VBIV with Shuxuening injection combined with betahistine can improve the blood flow velocity and hemorheology of vertebrobasilar artery, reduce the oxidative stress, and the curative effect is reliable. |
|
View Full Text
View/Add Comment Download reader |
| Close |
